Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2021 May 26

PMID 34036225

Citations 4

Authors

Marianne Spengler

Megan Wheelden

Heath B Mackley

Joseph J Drabick

Affiliations

Soon will be listed here.

Citing Articles

Isocitrate Dehydrogenase 2 (IDH2)-Mutant Metastatic Esthesioneuroblastoma: A Case Report and Review of Current Therapeutic Options.

Banha R, Fernandes R, Floudas C, Vieira C Cureus. 2025; 17(2):e78618.

PMID: 40062188 PMC: 11889986. DOI: 10.7759/cureus.78618.

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.

Hoshi Y, Enokida T, Tamura S, Nakashima T, Okano S, Fujisawa T Front Oncol. 2024; 14:1379013.

PMID: 38846982 PMC: 11153745. DOI: 10.3389/fonc.2024.1379013.

Genomic characterization of an esthesioneuroblastoma with spinal metastases: illustrative case.

Marin B, Leclair N, Shen E, Buehler A, Hegde U, Wu Q J Neurosurg Case Lessons. 2023; 6(23).

PMID: 38048560 PMC: 10701755. DOI: 10.3171/CASE23164.

Olfactory neuroblastoma: diagnosis, management, and current treatment options.

Tosoni A, Di Nunno V, Gatto L, Corradi G, Bartolini S, Ranieri L Front Oncol. 2023; 13:1242453.

PMID: 37909011 PMC: 10613987. DOI: 10.3389/fonc.2023.1242453.

The contemporary management of cancers of the sinonasal tract in adults.

Thawani R, Kim M, Arastu A, Feng Z, West M, Taflin N CA Cancer J Clin. 2022; 73(1):72-112.

PMID: 35916666 PMC: 9840681. DOI: 10.3322/caac.21752.

References

Chellappan D, Chellian J, Yin Ng Z, Sim Y, Theng C, Ling J . The role of pazopanib on tumour angiogenesis and in the management of cancers: A review. Biomed Pharmacother. 2017; 96:768-781. DOI: 10.1016/j.biopha.2017.10.058. View

Fury M, Sherman E, Haque S, Korte S, Lisa D, Shen R . A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011; 69(3):591-8. DOI: 10.1007/s00280-011-1734-5. View

McCormack P . Pazopanib: a review of its use in the management of advanced renal cell carcinoma. Drugs. 2014; 74(10):1111-25. DOI: 10.1007/s40265-014-0243-3. View

Sudarshan S, Linehan W, Neckers L . HIF and fumarate hydratase in renal cancer. Br J Cancer. 2007; 96(3):403-7. PMC: 2360036. DOI: 10.1038/sj.bjc.6603547. View

Abdelmeguid A . Olfactory Neuroblastoma. Curr Oncol Rep. 2018; 20(1):7. DOI: 10.1007/s11912-018-0661-6. View

Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi J . Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients. Cancer Res Treat. 2019; 51(4):1549-1556. PMC: 6790829. DOI: 10.4143/crt.2019.086. View

Morris M, Maina E, Morgan N, Gentle D, Astuti D, Moch H . Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol. 2004; 57(7):706-11. PMC: 1770369. DOI: 10.1136/jcp.2003.011767. View

Wang L, Ding Y, Wei L, Zhao D, Wang R, Zhang Y . Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report. Medicine (Baltimore). 2016; 95(18):e3536. PMC: 4863775. DOI: 10.1097/MD.0000000000003536. View

Sohrabi S, Drabick J, Crist H, Goldenberg D, Sheehan J, Mackley H . Neoadjuvant concurrent chemoradiation for advanced esthesioneuroblastoma: a case series and review of the literature. J Clin Oncol. 2011; 29(13):e358-61. DOI: 10.1200/JCO.2010.30.9278. View

10.

Gay L, Kim S, Fedorchak K, Kundranda M, Odia Y, Nangia C . Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. Oncologist. 2017; 22(7):834-842. PMC: 5507647. DOI: 10.1634/theoncologist.2016-0287. View

11.

Dunbar E, Pumphrey P, Bidari S . Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab. Rare Tumors. 2012; 4(2):e33. PMC: 3401161. DOI: 10.4081/rt.2012.e33. View

12.

Turri-Zanoni M, Maragliano R, Battaglia P, Giovannardi M, Antognoni P, Lombardi D . The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival. Oral Oncol. 2017; 74:21-29. DOI: 10.1016/j.oraloncology.2017.09.010. View

13.

Marinelli J, Janus J, Van Gompel J, Link M, Foote R, Lohse C . Esthesioneuroblastoma with distant metastases: Systematic review & meta-analysis. Head Neck. 2018; 40(10):2295-2303. DOI: 10.1002/hed.25209. View

14.

Preusser M, Hutterer M, Sohm M, Koperek O, Elandt K, Dieckmann K . Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. J Neurooncol. 2009; 97(2):305-8. DOI: 10.1007/s11060-009-0027-x. View

15.

Frampton J . Pazopanib: a Review in Advanced Renal Cell Carcinoma. Target Oncol. 2017; 12(4):543-554. DOI: 10.1007/s11523-017-0511-8. View

16.

Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D . Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2010; 78(4):992-7. DOI: 10.1016/j.ijrobp.2009.09.019. View

17.

Nakano K, Takahashi S . Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. Int J Mol Sci. 2018; 19(3). PMC: 5877600. DOI: 10.3390/ijms19030739. View

18.

Topcagic J, Feldman R, Ghazalpour A, Swensen J, Gatalica Z, Vranic S . Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas. PLoS One. 2018; 13(1):e0191244. PMC: 5764485. DOI: 10.1371/journal.pone.0191244. View

19.

Purohit B, Winder T, Maggio E, Kollias S . Aggressive primary olfactory neuroblastoma of the sphenoclival region: a case report and literature review. Laryngoscope. 2014; 125(4):822-5. DOI: 10.1002/lary.24925. View